Organon & Co (OGN)
16.24
+0.12
(+0.74%)
USD |
NYSE |
Nov 08, 14:17
Organon Revenue (TTM): 6.409B for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 6.409B |
| June 30, 2024 | 6.346B |
| March 31, 2024 | 6.347B |
| December 31, 2023 | 6.263B |
| September 30, 2023 | 6.15B |
| June 30, 2023 | 6.168B |
| March 31, 2023 | 6.145B |
| December 31, 2022 | 6.174B |
| Date | Value |
|---|---|
| September 30, 2022 | 6.292B |
| June 30, 2022 | 6.355B |
| March 31, 2022 | 6.365B |
| December 31, 2021 | 6.304B |
| September 30, 2021 | 6.314B |
| June 30, 2021 | 6.327B |
| March 31, 2021 | 6.258B |
| December 31, 2020 | 6.532B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
6.145B
Minimum
Mar 2023
6.532B
Maximum
Dec 2020
6.297B
Average
6.309B
Median
Revenue (TTM) Benchmarks
| Eli Lilly and Co | 40.86B |
| Biomarin Pharmaceutical Inc | 2.753B |
| Cassava Sciences Inc | -- |
| Ligand Pharmaceuticals Inc | 133.48M |
| TG Therapeutics Inc | 264.79M |